文献速递妇科

辅助化疗联合放疗在IIIC期子宫内膜癌中的获益因组织学分级而异

Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2017-09-13

该研究纳入2000至2012年Siteman癌症中心登记的199例IIIC期子宫内膜癌患者,评估不同辅助治疗的生存获益是否随组织学分级变化。结果显示,与无辅助治疗相比,放疗、化疗和放化疗分别使死亡风险降低57%、62%和83%;以放化疗为参照,无辅助治疗、放疗和化疗的死亡风险更高。分层分析显示,低级别患者中放疗和放化疗较无辅助治疗分别降低死亡风险67%和85%,高级别患者中化疗和放化疗分别降低72%和83%。作者认为放化疗应作为IIIC期子宫内膜癌的首选辅助治疗策略。

要点

  • 放化疗后生存优于无辅助治疗(p<0.001)、放疗(p=0.010)和化疗(p<0.001)。
  • 低级别患者中,放疗和放化疗较无辅助治疗分别降低死亡风险67%(p=0.039)和85%(p<0.001)。
  • 高级别患者中,化疗和放化疗较无辅助治疗分别降低死亡风险72%(p=0.003)和83%(p<0.001)。

核心结论

  • 研究结果提示,放化疗应作为IIIC期子宫内膜癌的首选辅助治疗策略。

研究设计与样本

  • 通过Siteman癌症中心登记处识别2000年至2012年间199例IIIC期子宫内膜癌患者。
  • 所有患者均接受手术分期,随后接受无辅助治疗、放疗、化疗或放化疗。
  • 采用Kaplan-Meier曲线和多变量Cox回归分析辅助治疗与总生存的关联,并按低级别或高级别分层探索分级与治疗的交互作用。

主要发现

  • 大多数患者接受放化疗(50.3%),其次为化疗(23.1%)、放疗(16.1%)和无辅助治疗(10.5%)。
  • 放化疗后生存优于无辅助治疗(p<0.001)、放疗(p=0.010)和化疗(p<0.001)。
  • 调整协变量后,与无辅助治疗相比,放疗、化疗和放化疗分别使死亡风险降低57%(p=0.024)、62%(p=0.003)和83%(p<0.001)。
  • 以放化疗为参照,调整后的死亡风险在无辅助治疗(5.94,p<0.001)、放疗(2.56,p=0.009)和化疗(2.24,p=0.004)中更高。
  • 按分级分层,低级别患者中放疗和放化疗较无辅助治疗分别降低死亡风险67%(p=0.039)和85%(p<0.001);高级别患者中化疗和放化疗较无辅助治疗分别降低死亡风险72%(p=0.003)和83%(p<0.001)。

临床怎么用

  • 作者认为,放化疗应作为IIIC期子宫内膜癌患者的首选辅助治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The optimal strategy for adjuvant therapy in stage IIIC endometrial cancer has not been determined. Our aim was to evaluate survival benefit of different treatments and to investigate if benefit varied by histologic grade. METHODS: We identified 199 patients with stage IIIC endometrial cancer from 2000 to 2012 through the Siteman Cancer Center registry. All patients underwent surgical staging followed by no adjuvant therapy (NAT), radiation (RT), chemotherapy (CT) or chemoradiation (CRT). The association between adjuvant treatment and overall survival was explored using Kaplan-Meier plots and multivariable Cox regression analysis. Multivariable analysis was stratified by low- or high-grade to explore the interaction between grade and treatment. RESULTS: Most patients received CRT (50.3%) followed by CT (23.1%), RT (16.1%) and NAT (10.5%). Survival after CRT was superior to NAT (p<0.001), RT (p=0.010) and CT (p<0.001). After adjusting for covariates, treatment with RT, CT and CRT led to a 57% (p=0.024), 62% (p=0.003) and 83% (p<0.001) reduction in risk of death compared to NAT, respectively. With CRT as the reference, the adjusted hazard of death was higher with NAT (5.94, p<0.001), RT (2.56, p=0.009) and CT (2.24, p=0.004). Stratifying by grade, RT and CRT led to a 67% (p=0.039) and 85% (p<0.001) reduction in death, compared to NAT in low-grade patients. CT and CRT led to a 72% (p=0.003) and 83% (p<0.001) reduction in death, compared to NAT in high-grade patients. CONCLUSIONS: Our findings suggest that CRT should be the preferred adjuvant treatment strategy for patients with stage IIIC endometrial cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Binder PS, Kuroki LM, Zhao P, et al. Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer. Gynecol Oncol. 2017. PMID: 28916118. doi:10.1016/j.ygyno.2017.08.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。